DossierENTITY

VESPER-3

Coverage of VESPER-3 in the Nexus archive.

Earliest in view: Jun 6 · 13:00 UTCMost recent: Jun 6 · 13:00 UTC

Co-mentioned in this coverage

Recent coverage

HEALTHJun 6 · 13:00 UTCSTAT NEWS
STAT+: Detailed data show Pfizer’s monthly obesity drug continues to show potential
Pfizer's obesity drug berobenatide, acquired from Metsera, showed continued weight loss when transitioning from weekly to monthly dosing in a mid-stage study. Patients lost up to 12.1% of their weight by 28 weeks, but the rate lagged behind Eli Lilly's Zepbound trial results.